Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrafy Life SciencesASX:VFY -1.53%4 Cash Ratio is 23.09 as of Jun. 2026, which is at its 10-year median of 23.09. GuruFocus rates ASX:VFY with a GF Score™ of 4/100. The stock has 2 warning signs investors should review. Among 2,810 Software companies, Vitrafy Life Sciences ranks better than 99.07% on this metric.
Vitrafy Life Sciences has a Cash Ratio of 23.09. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Vitrafy Life Sciences's Cash Ratio or its related term are showing as below:
ASX:VFY'
s Cash Ratio Range Over the Past 10 Years
Min: 10.86 Med: 23.09 Max: 44.88
Current: 23.09
During the past 5 years, Vitrafy Life Sciences's highest Cash Ratio was 44.88. The lowest was 10.86. And the median was 23.09.
ASX:VFY's Cash Ratio is ranked better than 99.07% of 2810
companies
in the Software industry
Industry Median: 0.76
vs ASX:VFY: 23.09
Vitrafy Life Sciences (ASX:VFY) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VFY vs MSFT, PLTR, ORCL: Cash Ratio Comparison
For the Software - Infrastructure subindustry, Vitrafy Life Sciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrafy Life Sciences Cash Ratio vs Software Industry
For the Software industry and Technology sector, Vitrafy Life Sciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Vitrafy Life Sciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrafy Life Sciences (ASX:VFY) has a Cash Ratio of 23.09 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Vitrafy Life Sciences and its competitors. This is near median its historical median of 23.09. Over the past decade, Vitrafy Life Sciences' Cash Ratio has ranged from 10.86 to 44.88. According to the industry distribution chart, Vitrafy Life Sciences ranks #26 out of 2810 companies in the Software industry, placing it in the top 0.90000000000001%.
Is Vitrafy Life Sciences' Cash Ratio too high?
Vitrafy Life Sciences' current Cash Ratio of 23.09 is near median its 10-year median of 23.09. Over the past 10 years, this metric has ranged from a low of 10.86 to a high of 44.88. The Software industry median Cash Ratio is 0.76. Vitrafy Life Sciences' value of 23.09 is 2938.2% above this industry median. Based on the distribution chart, Vitrafy Life Sciences ranks #26 out of 2810 companies in the Software industry, which is in the top quartile — a strong position relative to peers. Overall, Vitrafy Life Sciences has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Vitrafy Life Sciences' Cash Ratio compare to MSFT and PLTR?
According to the Software industry distribution chart, Vitrafy Life Sciences ranks #26 out of 2810 companies for Cash Ratio. This places Vitrafy Life Sciences in the top 1% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.76. Vitrafy Life Sciences' value of 23.09 is 2938.2% above this benchmark. Historically, Vitrafy Life Sciences' own Cash Ratio has ranged from 10.86 to 44.88 over the past decade. While the company's 10-year median is 23.09 vs. the industry median of 0.76, Vitrafy Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Software company?
The median Cash Ratio among Software companies is 0.76, based on 2,810 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrafy Life Sciences's current Cash Ratio of 23.09 is 2938.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Vitrafy Life Sciences and its competitors. For the Software industry, the median Cash Ratio is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrafy Life Sciences's current Cash Ratio is 23.09, which is near median its own 10-year median of 23.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrafy Life Sciences stock overvalued right now?
Vitrafy Life Sciences (ASX:VFY) has a current Cash Ratio of 23.09. The current Cash Ratio is 23.09, which is near median its 10-year median of 23.09 and 2938.2% above the Software industry median of 0.76. Vitrafy Life Sciences' overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Vitrafy Life Sciences (ASX:VFY), the current Cash Ratio is 23.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitrafy Life Sciences Ltd developed a range of proprietary smart cryopreservation hardware devices and Lifechain, an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials. The company devices includes Vitrafy's Smart Cryopreservation Device; Vitrafy's Smart Thawing Device and Vitrafy's Smart Packaging.
4GF Score
Get the complete analysis for ASX:VFY
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VFY has been successfully added to your 
